📣 VC round data is live. Check it out!
- Public Comps
- TriSalus Life Sciences
TriSalus Life Sciences Valuation Multiples
Discover revenue and EBITDA valuation multiples for TriSalus Life Sciences and similar public comparables like RxSight, Ilex Medical, Asterasys, Medinice and more.
TriSalus Life Sciences Overview
About TriSalus Life Sciences
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.
Founded
2020
HQ

Employees
110
Website
Financials (LTM)
EV
$183M
Valuation Multiples
Start free trialTriSalus Life Sciences Financials
TriSalus Life Sciences reported last 12-month revenue of $49M and negative EBITDA of ($15M).
In the same LTM period, TriSalus Life Sciences generated $41M in gross profit, ($15M) in EBITDA losses, and had net loss of ($30M).
Revenue (LTM)
TriSalus Life Sciences P&L
In the most recent fiscal year, TriSalus Life Sciences reported revenue of $45M and EBITDA of ($17M).
TriSalus Life Sciences is unprofitable as of last fiscal year, with gross margin of 85%, EBITDA margin of (37%), and net margin of (87%).
Financial data powered by Morningstar, Inc.
TriSalus Life Sciences Stock Performance
TriSalus Life Sciences has current market cap of $205M, and enterprise value of $183M.
Market Cap Evolution
TriSalus Life Sciences' stock price is $3.33.
TriSalus Life Sciences share price decreased by 2.5% in the last 30 days, and by 38.8% in the last year.
TriSalus Life Sciences has an EPS (earnings per share) of $-0.64.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $183M | $205M | -9.3% | -2.5% | -16.5% | -38.8% | $-0.64 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialTriSalus Life Sciences Valuation Multiples
TriSalus Life Sciences trades at 3.7x EV/Revenue multiple, and (12.2x) EV/EBITDA.
EV / Revenue (LTM)
TriSalus Life Sciences Financial Valuation Multiples
As of June 3, 2026, TriSalus Life Sciences has market cap of $205M and EV of $183M.
TriSalus Life Sciences has a P/E ratio of (6.7x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified TriSalus Life Sciences Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


TriSalus Life Sciences Margins & Growth Rates
TriSalus Life Sciences grew revenue by 19% but EBITDA decreased by 22% in the last fiscal year.
In the most recent fiscal year, TriSalus Life Sciences reported gross margin of 85%, EBITDA margin of (37%), and net margin of (87%).
TriSalus Life Sciences Margins
TriSalus Life Sciences Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
TriSalus Life Sciences Operational KPIs
TriSalus Life Sciences' revenue per employee in the last FY averaged $0.4M, while opex per employee averaged $0.6M for the same period.
TriSalus Life Sciences' Rule of 40 is (5%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
TriSalus Life Sciences' Rule of X is 23% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
TriSalus Life Sciences Competitors
TriSalus Life Sciences competitors include RxSight, Ilex Medical, Asterasys, Medinice, Lucid Diagnostics, Pro-Dex, Huons Co, Utah Medical, Sanara MedTech and Anika Therapeutics.
Most TriSalus Life Sciences public comparables operate across Medical Devices, DeepTech, HealthTech and BioTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| (0.0x) | (0.0x) | 0.1x | 0.0x | |||
| 0.4x | - | 3.3x | - | |||
| 7.5x | 6.3x | 22.7x | 18.2x | |||
| - | - | (111.9x) | - | |||
| 44.1x | 35.6x | (3.7x) | (4.0x) | |||
| 3.3x | 2.9x | 15.7x | - | |||
| 0.7x | - | 5.2x | - | |||
| 3.3x | - | 8.8x | - | |||
This data is available for Pro users. Sign up to see all TriSalus Life Sciences competitors and their valuation data. Start Free Trial | ||||||
TriSalus Life Sciences VC Funding History
Before going public, TriSalus Life Sciences raised $70M in total equity funding, across 4 rounds.
TriSalus Life Sciences Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout TriSalus Life Sciences
| When was TriSalus Life Sciences founded? | TriSalus Life Sciences was founded in 2020. |
| Where is TriSalus Life Sciences headquartered? | TriSalus Life Sciences is headquartered in United States. |
| How many employees does TriSalus Life Sciences have? | As of today, TriSalus Life Sciences has over 110 employees. |
| Who is the CEO of TriSalus Life Sciences? | TriSalus Life Sciences' CEO is Mary T. Szela. |
| Is TriSalus Life Sciences publicly listed? | Yes, TriSalus Life Sciences is a public company listed on Nasdaq. |
| What is the stock symbol of TriSalus Life Sciences? | TriSalus Life Sciences trades under TLSI ticker. |
| When did TriSalus Life Sciences go public? | TriSalus Life Sciences went public in 2023. |
| Who are competitors of TriSalus Life Sciences? | TriSalus Life Sciences main competitors include RxSight, Ilex Medical, Asterasys, Medinice, Lucid Diagnostics, Pro-Dex, Huons Co, Utah Medical, Sanara MedTech, Anika Therapeutics. |
| What is the current market cap of TriSalus Life Sciences? | TriSalus Life Sciences' current market cap is $205M. |
| What is the current revenue of TriSalus Life Sciences? | TriSalus Life Sciences' last 12 months revenue is $49M. |
| What is the current revenue growth of TriSalus Life Sciences? | TriSalus Life Sciences revenue growth (NTM/LTM) is 32%. |
| What is the current EV/Revenue multiple of TriSalus Life Sciences? | Current revenue multiple of TriSalus Life Sciences is 3.7x. |
| Is TriSalus Life Sciences profitable? | No, TriSalus Life Sciences is not profitable. |
| What is the current EBITDA of TriSalus Life Sciences? | TriSalus Life Sciences has negative EBITDA and is not profitable. |
| What is TriSalus Life Sciences' EBITDA margin? | TriSalus Life Sciences' last 12 months EBITDA margin is (31%). |
| What is the current EV/EBITDA multiple of TriSalus Life Sciences? | Current EBITDA multiple of TriSalus Life Sciences is (12.2x). |
| How many companies TriSalus Life Sciences has acquired to date? | TriSalus Life Sciences hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies TriSalus Life Sciences has invested to date? | TriSalus Life Sciences hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to TriSalus Life Sciences
Lists including TriSalus Life Sciences
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.